Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 May;138(Pt 5):1271-83.
doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease

Caroline Moreau  1 , Sayah Meguig  2 , Jean-Christophe Corvol  3 , Julien Labreuche  4 , Francis Vasseur  4 , Alain Duhamel  4 , Arnaud Delval  1 , Thomas Bardyn  2 , Jean-Christophe Devedjian  5 , Nathalie Rouaix  2 , Gregory Petyt  6 , Christine Brefel-Courbon  7 , Fabienne Ory-Magne  7 , Dominique Guehl  8 , Alexandre Eusebio  9 , Valérie Fraix  10 , Pierre-Jean Saulnier  11 , Ouhaid Lagha-Boukbiza  12 , Frank Durif  13 , Mirela Faighel  14 , Caroline Giordana  15 , Sophie Drapier  16 , David Maltête  17 , Christine Tranchant  12 , Jean-Luc Houeto  11 , Bettina Debû  10 , Jean-Philippe Azulay  9 , François Tison  8 , Alain Destée  18 , Marie Vidailhet  6 , Olivier Rascol  19 , Kathy Dujardin  1 , Luc Defebvre  1 , Régis Bordet  20 , Bernard Sablonnière  2 , David Devos  21 ; Parkgait-II Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease

Caroline Moreau et al. Brain. 2015 May.

Abstract

After more than 50 years of treating Parkinson's disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is the most powerful determinant of dopamine neurotransmission and might therefore influence the treatment response. We recently demonstrated that methylphenidate (a dopamine transporter inhibitor) is effective in patients with Parkinson's disease with motor and gait disorders. The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). This analysis was part of a multicentre, parallel-group, double-blind, placebo-controlled, randomized clinical trial of methylphenidate in Parkinson's disease (Protocol ID:2008-005801-20; ClinicalTrials.gov:NCT00914095). We scored the motor Unified Parkinson's Disease Rating Scale and the Stand-Walk-Sit Test before and after a standardized acute l-DOPA challenge before randomization and then after 3 months of methylphenidate treatment. Patients were screened for variants of genes involved in dopamine metabolism: rs28363170 and rs3836790 polymorphisms in the SLC6A3 gene, rs921451 and rs3837091 in the DDC gene (encoding the aromatic L-amino acid decarboxylase involved in the synthesis of dopamine from l-DOPA), rs1799836 in the MAOB gene (coding for monoamine oxidase B) and rs4680 in the COMT gene (coding for catechol-O-methyltransferase). Investigators and patients were blinded to the genotyping data throughout the study. Eighty-one subjects were genotyped and 61 were analysed for their acute motor response to l-DOPA. The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. The difference between motor Unified Parkinson's Disease Rating Scale scores for patients with different SLC6A3 genotypes was statistically significant in a multivariate analysis that took account of other disease-related, treatment-related and pharmacogenetic parameters. Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson's disease. Further studies are required to assess the possible value of these genotypes for (i) guiding l-DOPA dose adaptations over the long term; and (ii) establishing the risk/benefit balance associated with methylphenidate treatment for gait disorders.

Keywords: Parkinson’s disease; cognitive disorders; levodopa; methylphenidate; pharmacogenetics.

PubMed Disclaimer

Figures

None
Responses to L-dopa vary within and between individuals. Moreau et al. reveal that polymorphisms in the dopamine transporter gene (SLC6A3) influence the response to L-dopa and to the dopamine transporter inhibitor methylphenidate. This may help physicians to optimise L-dopa dose and to assess the risk/benefit balance for treatment with methylphenidate.
Figure 1
Figure 1
Flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bergersen L, Gauvreau K, Marshall A, Kreutzer J, Beekman R, Hirsch R, et al. Procedure-type risk categories for pediatric and congenital cardiac catheterization. Circ Cardiovasc Interv 2011; 4: 188–94. - PubMed
    1. Berry MD, Juorio AV, Li XM, Boulton AA. Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res. 1996;21:1075–87. - PubMed
    1. Białecka M, Droździk M, Kłodowska-Duda G, Honczarenko K, Gawrońska-Szklarz B, Opala G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand. 2004;110:260–6. - PubMed
    1. Białecka M, Kurzawski M, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics. 2008;18:815–21. - PubMed
    1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–74. - PubMed

Publication types

Associated data